- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
ALK Inhibitors in Nonsmall Cell Lung Cancer ; volume:42 ; number:01 ; year:2021 ; pages:067-070
Indian journal of medical & paediatric oncology ; 42, Heft 01 (2021), 067-070
- Beteiligte Personen und Organisationen
-
Garg, Nitish
Kothari, Rushabh
- DOI
-
10.1055/s-0041-1729728
- URN
-
urn:nbn:de:101:1-2021081213511943038716
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:52 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Garg, Nitish
- Kothari, Rushabh
Ähnliche Objekte (12)
Second- and third-generation ALK inhibitors for non-small cell lung cancer
The combined effect of ALK inhibitors and radiotherapy in non-small cell lung cancer
Gingival Metastasis of ALK Rearranged Non-Small Cell Lung Cancer
Retrospective Observational Study of ALK-Inhibitor Therapy Sequencing and Outcomes in Patients with ALK-Positive Non-small Cell Lung Cancer
Current knowledge about mechanisms of drug resistance against ALK inhibitors in non-small cell lung cancer
Comparing Genomic Profiles of ALK Fusion-Positive and ALK Fusion-Negative Nonsmall Cell Lung Cancer Patients
Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK ‐rearranged lung cancer
Primary Resistance to ALK Inhibitors in a Patient with Nonsmall Cell Lung Cancer with ALK Rearrangement: A Case Report with Review of Literature
Discovery of a novel ALK/ROS1/FAK inhibitor, APG-2449, in preclinical non-small cell lung cancer and ovarian cancer models
New pan-ALK inhibitor-resistant EML4::ALK mutations detected by liquid biopsy in lung cancer patients
Inconsistent results in the analysis of ALK rearrangements in non-small cell lung cancer
Iruplinalkib (WX‑0593), a novel ALK/ROS1 inhibitor, overcomes crizotinib resistance in preclinical models for non-small cell lung cancer
Second- and third-generation ALK inhibitors for non-small cell lung cancer
The combined effect of ALK inhibitors and radiotherapy in non-small cell lung cancer
Gingival Metastasis of ALK Rearranged Non-Small Cell Lung Cancer
Retrospective Observational Study of ALK-Inhibitor Therapy Sequencing and Outcomes in Patients with ALK-Positive Non-small Cell Lung Cancer
Current knowledge about mechanisms of drug resistance against ALK inhibitors in non-small cell lung cancer
Comparing Genomic Profiles of ALK Fusion-Positive and ALK Fusion-Negative Nonsmall Cell Lung Cancer Patients
Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK ‐rearranged lung cancer
Primary Resistance to ALK Inhibitors in a Patient with Nonsmall Cell Lung Cancer with ALK Rearrangement: A Case Report with Review of Literature
Discovery of a novel ALK/ROS1/FAK inhibitor, APG-2449, in preclinical non-small cell lung cancer and ovarian cancer models
New pan-ALK inhibitor-resistant EML4::ALK mutations detected by liquid biopsy in lung cancer patients
Inconsistent results in the analysis of ALK rearrangements in non-small cell lung cancer
Iruplinalkib (WX‑0593), a novel ALK/ROS1 inhibitor, overcomes crizotinib resistance in preclinical models for non-small cell lung cancer
Second- and third-generation ALK inhibitors for non-small cell lung cancer
The combined effect of ALK inhibitors and radiotherapy in non-small cell lung cancer
Gingival Metastasis of ALK Rearranged Non-Small Cell Lung Cancer
Retrospective Observational Study of ALK-Inhibitor Therapy Sequencing and Outcomes in Patients with ALK-Positive Non-small Cell Lung Cancer
Current knowledge about mechanisms of drug resistance against ALK inhibitors in non-small cell lung cancer
Comparing Genomic Profiles of ALK Fusion-Positive and ALK Fusion-Negative Nonsmall Cell Lung Cancer Patients
Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK ‐rearranged lung cancer
Primary Resistance to ALK Inhibitors in a Patient with Nonsmall Cell Lung Cancer with ALK Rearrangement: A Case Report with Review of Literature
Discovery of a novel ALK/ROS1/FAK inhibitor, APG-2449, in preclinical non-small cell lung cancer and ovarian cancer models
New pan-ALK inhibitor-resistant EML4::ALK mutations detected by liquid biopsy in lung cancer patients
Inconsistent results in the analysis of ALK rearrangements in non-small cell lung cancer